紅麹で入院、４９２人に　腎疾患以外も公表―厚労省

　小林製薬の「紅麹（べにこうじ）」配合サプリメントを巡る健康被害問題で、厚生労働省は２日、入院者数（先月３０日時点）は延べ４９２人と発表した。うち腎疾患の患者は２９１人。同省はこれまで、腎臓に異常がみられる事例のみ公表していたが、今回からそれ以外の症状も含めた。
　同省によると、医療機関の受診者数（同日時点）は延べ２２２１人で、うち腎疾患がある人は１６６０人。遺族からの死亡相談は１７５人で変わらない。（2024/07/02-21:35）

The cumulative number of people hospitalized in relation to Kobayashi Pharmaceutical Co.'s supplements containing "beni koji" red fermented rice had reached 492 as of Sunday, Japan's health ministry said Tuesday.
   Of them, 291 had kidney disease. The latest tally newly included cases other than sufferers of kidney problems.
   According to the ministry, a total of 2,221 people had been examined at medical institutions over the supplements as of Sunday, including 1,660 kidney disease sufferers.
   The number of fatal cases with possible links with the supplements reported by bereaved family members was unchanged at 175.
   Kobayashi Pharmaceutical said in March that five fatal cases had been reported by bereaved families. But the company told the ministry last week that it had received consultations about 170 more deaths possibly linked to its supplements.